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Background
A medication review is defined as a structured, critical examination of a patient's medications with the objectives of reaching an agreement with the patient about his or her treatment and optimizing the impact of medications on the patient's health. 1 Most provinces in Canada have recently implemented government-sponsored programs to compensate community pharmacies for providing medication reviews to patients who meet predefined eligibility requirements. Ontario was the first province to remunerate community pharmacies for a standardized medication review program in 2007 called MedsCheck. Since 2007, similar programs have appeared in other provinces. The remuneration provided to pharmacies ranges from $52.50 to $150 per review, with some programs offering $15 to $35 for follow-up services.
While the operational details and terminology of each program differ to some degree, all of these programs share the common goal of having a pharmacist meet with patients to provide education about the medications they are taking, to provide the patients (and pharmacy) with a current best possible medication history, to identify and address drug therapy problems and to elucidate and monitor patients' progress toward the goals of their drug therapy.
The provincial funding available for these programs is limited, and pharmacist time continues to be at a premium. Consequently, each province has limited access to these services by developing strict eligibility criteria. The presumed goal of the criteria is to ensure that these new programs improve patient outcomes and use public resources responsibly, by providing the service to patients who will benefit the most. This article is intended to provide an overview of the eligibility criteria for provincially funded medication review programs across Canada.
Methods
An environmental scan was performed by accessing the websites of each province's or territory's Ministry of Health and pharmacy professional associations (in June 2013) to determine the eligibility criteria being used for any publicly funded, community pharmacybased medication review program. Documents relating to each jurisdiction's provincially funded pharmacist cognitive services were reviewed. The accuracy of the documents was verified by contacting each professional association directly (via e-mail and telephone; from June to July 2013).
Results
Eight of the 10 provinces in Canada were found to have a provincially funded program that we considered to be a medication review, although not all use this term to describe the service being provided. Manitoba, Quebec and the territories offer a variety of clinical programs in the community pharmacy setting (such as Quebec's Opinion Pharmaceutique); they do not offer a provincially funded medication review program similar to the other provinces and are therefore not included in this review. Table 1 contains an overview of the eligibility requirements of these provincial programs. Some provinces offered more than one variation of the service, which is reflected in Table 1 . Common aspects such as the 
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need for patient consent and the requirement that the review be performed in person have not been included in the table. There is also an implied expectation within each medication review program that pharmacists use their professional judgment and only offer the service to those patients who meet the prespecified eligibility criteria and who (the pharmacists believe) need the service. Some provinces have explicit definitions of what constitutes patient need, and those definitions are included in Table 1 .
Discussion
The most striking aspect of the results of this policy review is the lack of consistency with respect to the eligibility criteria used by each provincial program. Although the programs provide similar clinical pharmacist interventions, there appears to be little congruence among programs regarding the patients who are eligible to receive the services. Some programs require patients to be taking a minimum number of chronic medications to be eligible (but no consistent number of medications is used), while other programs are available to patients taking certain high-risk medications (e.g., anticoagulants) or patients with specific chronic diseases (e.g., diabetes), regardless of the number of medications taken. Some programs use a combination of these approaches, where eligible patients must suffer from a specific chronic disease and must be taking a minimum number or type of medications. Very few programs were found to use exactly the same eligibility criteria. The most commonly used criterion is that patients must be taking at least 3 medications to be eligible for the medication review (PEI Basic Medication Review, Nova Scotia Basic Medication Review Service, Ontario MedsCheck and MedsCheck at Home). However, there is also a program that uses 4 or more medications as the cutoff (Nova Scotia Advanced Medication Review Service), another that uses 5 or more medications (British Columbia Medication Review Services) and still another that covers patients taking 5 or more medications who are also age 65 and over (Saskatchewan Medication Assessment Program). There is a similar lack of consistency among programs that use specific medications (e.g., anticoagulants, Beers Criteria drugs, drugs for the treatment of diabetes) or chronic diseases (e.g., diabetes, mental illness) to define eligibility criteria.
The prevailing similarity in the eligibility criteria for these programs is that most appear to be based on known risk factors for preventable Individuals must have at least 1 "chronic condition" ‡ and must be taking at least 3 different prescription medications or 2 prescription medications and insulin. Clinical need is obtained when a prescriber requests a medication review, the patient has multiple diseases, the patient has chronic diseases, the patient's medication regimen includes 1 or more nonprescription medications, the patient's medication regimen includes 1 or more natural health products, the patient has a drug therapy problem, the patient was recently discharged from hospital, the patient has multiple prescribers and/or the patient is receiving a medication that requires laboratory monitoring. [15] [16] [17] Unfortunately, the evidence supporting these risk factors does not provide clear thresholds for people who are "high risk" or "low risk, " making it very difficult to use these risk factors to create appropriate eligibility criteria for medication review programs. It is completely understandable that provincial health ministries have focused on a risk factor approach for developing medication review program eligibility criteria. After performing an extensive literature search, we were unable to identify a single screening tool or protocol previously validated within a community pharmacy setting to identify patients who will benefit the most from pharmacist-delivered clinical services such as medication reviews. The lack of an existing validated and evidencebased process for identifying people at highest risk (who would theoretically benefit most from a medication review) may be one explanation for the wide variation in eligibility criteria observed in the medication review programs across Canada. We recognize that other local factors, such as differences in provincial health care priorities and the size of the budget allotted to these programs, likely also contribute to the variation. Considering that evidence-based eligibility criteria do not exist for pharmacist-led medication reviews, it is essential that existing provincial programs be evaluated to ensure they are enrolling appropriate patients who are benefitting from the service.
Conclusion
The eligibility criteria used by provincially funded medication review programs in Canada are inconsistent and highly variable, raising doubt that all patients in need of such services are eligible to receive them as an insured health benefit. The development of a validated tool or screening protocol that is capable of identifying patients who will benefit from a medication review would allow provincially funded medication review programs to adopt consistent eligibility criteria that would make it more likely that health care resources are used responsibly and patient outcomes are improved optimally. ■ From the College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan. Contact derek.jorgenson@usask.ca.
